{"text_format":"3","workbook":"xls","n_sheets":1,"sheets":["Table. 1"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Table. 1","index":0,"n_rows":40,"n_cols":2,"rows_kept":40,"merged":[[39,0,42,1]],"flags":["formulas_cached_only"]}
[]
[]
["Characteristic (n=34)"]
["Age (years), median (range)","71 (49-87)"]
[]
["Male sex, n (%)","28 (76.5)"]
[]
["ECOG PS score, n (%)"]
[0,"18 (52.9)"]
[1,"12 (35.3)"]
[2,"4 (11.8)"]
[]
["Primary tumor site, n (%)"]
["  Bladder","14 (41.2)"]
["  Upper urinary tract","14 (41.2)"]
["  Bladder + upper urinary tract","6 (17.6)"]
[]
["Pure UC in histologic testing, n (%)","28 (82.4)"]
[]
["First-line chemotherapy regimens"]
["GC","27 (79.4)"]
["GCarbo","6 (20.6)"]
[]
["Number of chemotherapy cycles before pembrolizumab"]
["≤4 cycles","22 (64.7)"]
["5, 6 cycles","4 (11.8)"]
["≥7 cycles","8 (23.5)"]
[]
["Hb <10 g/dl, n (%)","12 (35.3)"]
[]
["NLR, median (range)","1.9 (0.7-18.0)"]
[]
["Albumin <4.1 g/dl, n (%)","21 (61.8)"]
[]
["LDH >222 U/L, n (%)","11 (32.4)"]
[]
["Liver metastases, n (%)","7 (20.6)"]
[]
["Time from previous chemotherapy <3 months, n (%)","27 (79.4)"]
["ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; GC, gemcitabine + cisplatin; GCarbo, gemcitabine + carboplatin; Hb, hemoglobin; NLR, neutrophil/lymphocyte ratio; LDH, lactate dehydrogenase"]